Shanghai Yizhong Pharmaceutical Co., Ltd. (SHA:688091)
China · Delayed Price · Currency is CNY 35.57
-1.41 (-3.81%)
Nov 13, 2026, 3:00 PM CST
SHA:688091 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 325.8 | 315.57 | 173.03 | 359.75 | 235.7 | 4.08 |
Other Revenue | 0.25 | 0.51 | 0.51 | 0.51 | 0.25 | - |
| 326.06 | 316.08 | 173.53 | 360.25 | 235.96 | 4.08 | |
Revenue Growth | 31.98% | 82.14% | -51.83% | 52.68% | 5686.76% | - |
Cost of Revenue | 51.45 | 54.67 | 13.34 | 23.62 | 16.97 | 0.3 |
Gross Profit | 274.61 | 261.4 | 160.2 | 336.63 | 218.99 | 3.78 |
Selling, General & Admin | 111.33 | 125.9 | 143.05 | 147.57 | 98.64 | 17.29 |
Research & Development | 112.09 | 86.37 | 37.2 | 22.45 | 7.93 | 13.24 |
Other Operating Expenses | -0.69 | 1.34 | 1.01 | 1.61 | 0.9 | 0.03 |
Operating Expenses | 220.04 | 217.74 | 176.21 | 177.07 | 109.51 | 30.77 |
Operating Income | 54.56 | 43.66 | -16.01 | 159.57 | 109.48 | -26.99 |
Interest Expense | -0.07 | -0.07 | -0.7 | -0.27 | - | -0.59 |
Interest & Investment Income | 1.97 | 17.1 | 25.04 | 34.35 | 30.32 | 8.6 |
Other Non Operating Income (Expenses) | 11.62 | -0.01 | -0.09 | -0.05 | -0 | -0.02 |
EBT Excluding Unusual Items | 68.09 | 60.69 | 8.24 | 193.59 | 139.79 | -19 |
Gain (Loss) on Sale of Investments | -0.92 | 0.73 | - | 0.42 | 0.9 | 3.25 |
Gain (Loss) on Sale of Assets | - | - | -0 | - | - | - |
Asset Writedown | -1.94 | - | - | - | - | - |
Other Unusual Items | -0.8 | -0.27 | -3.42 | -7.11 | 8.87 | 6.47 |
Pretax Income | 64.42 | 61.15 | 4.82 | 186.9 | 149.56 | -9.28 |
Income Tax Expense | -5.27 | -3.41 | -2.16 | 25.35 | 6.71 | -5.28 |
Net Income | 69.69 | 64.56 | 6.98 | 161.55 | 142.85 | -4 |
Net Income to Common | 69.69 | 64.56 | 6.98 | 161.55 | 142.85 | -4 |
Net Income Growth | 203.48% | 825.49% | -95.68% | 13.09% | - | - |
Shares Outstanding (Basic) | 205 | 202 | 233 | 158 | 206 | 156 |
Shares Outstanding (Diluted) | 205 | 202 | 233 | 158 | 206 | 156 |
Shares Change | -11.57% | -13.23% | 46.80% | -23.24% | 32.68% | 2.51% |
EPS (Basic) | 0.34 | 0.32 | 0.03 | 1.02 | 0.69 | -0.03 |
EPS (Diluted) | 0.34 | 0.32 | 0.03 | 1.02 | 0.69 | -0.03 |
EPS Growth | 243.18% | 966.67% | -97.06% | 47.34% | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -17.21 | -149.47 | -40.6 | 77.77 | 74.9 | -51.93 |
Free Cash Flow Per Share | -0.08 | -0.74 | -0.17 | 0.49 | 0.36 | -0.33 |
Dividend Per Share | - | - | - | 0.031 | 0.210 | - |
Dividend Growth | - | - | - | -85.22% | - | - |
Gross Margin | 84.22% | 82.70% | 92.31% | 93.44% | 92.81% | 92.75% |
Operating Margin | 16.73% | 13.81% | -9.23% | 44.29% | 46.40% | -661.96% |
Profit Margin | 21.37% | 20.42% | 4.02% | 44.84% | 60.54% | -98.03% |
Free Cash Flow Margin | -5.28% | -47.29% | -23.40% | 21.59% | 31.74% | -1273.49% |
EBITDA | 67.17 | 55.65 | -4.85 | 167.45 | 115.91 | -20.4 |
EBITDA Margin | 20.60% | 17.61% | -2.79% | 46.48% | 49.12% | - |
D&A For EBITDA | 12.6 | 11.99 | 11.16 | 7.88 | 6.43 | 6.59 |
EBIT | 54.56 | 43.66 | -16.01 | 159.57 | 109.48 | -26.99 |
EBIT Margin | 16.73% | 13.81% | -9.23% | 44.29% | 46.40% | - |
Effective Tax Rate | - | - | - | 13.56% | 4.48% | - |
Revenue as Reported | - | 316.08 | 173.53 | 360.25 | 235.96 | 4.08 |
Advertising Expenses | - | - | - | - | - | 0.33 |